Related Experiment Video
Updated: Jun 3, 2026

07:44
TMT Sample Preparation for Proteomics Facility Submission and Subsequent Data Analysis
Published on: June 8, 2020
Quantitative profiling of serum samples using TMT protein labelling, fractionation and LC-MS/MS
1Cancer Proteomics Laboratory, EGA Institute for Women's Health, University College London UCL, Cruciform Building, Gower St., London WC1E 6BT, UK.
Methods (San Diego, Calif.)
|March 15, 2011
Summary
This study introduces a new quantitative method for analyzing serum proteins, improving biomarker discovery for early disease detection. The approach offers broader proteome coverage compared to existing peptide-based methods.
Area of Science:
- Biochemistry
- Proteomics
- Biomarker Discovery
Background:
- Early disease detection relies on identifying reliable blood-borne biomarkers.
- Current methods for serum and plasma protein profiling need enhancement for effective biomarker discovery.
Purpose of the Study:
- To develop and validate a novel quantitative method for serum protein profiling.
- To improve the coverage and accuracy of proteomic analysis for biomarker discovery.
Main Methods:
- Quantitative analysis using amino-group labeling of serum proteins with isobaric tandem tags (TMT).
- Integration of immune-based depletion, gel electrophoresis, and anion exchange chromatography for protein separation.
- Differential endoproteinase treatment followed by liquid chromatography-tandem mass spectrometry.
Main Results:
- Achieved higher quantitative coverage of the serum proteome compared to peptide-based isobaric tagging methods.
- Demonstrated the method's potential by analyzing pre-diagnostic pancreatic cancer samples.
- Successfully quantified a wider range of serum proteins.
Conclusions:
- The developed protein-based quantitative method enhances serum proteome coverage for biomarker discovery.
- This technique shows promise for early disease detection, particularly for conditions like pancreatic cancer.
- The method provides a more comprehensive approach to biomarker identification in clinical proteomics.
